(Total Views: 504)
Posted On: 08/13/2020 12:30:36 PM
Post# of 153890
BF, I think if we could streamline the awareness message to our contacts that would be very very helpful.Consistent message to all. A lot on the board have made "mock PR's" that they think would work. It could be a "board" effort that included study results but concise and impactful. Any thoughts?
Headline " CytoDyn a small biotech, submits to FDA its' COVID 19 drug, Leronlimab, for EUA approval. Leronlimab, an Immune Modulator, is the FIRST DRUG in the MM category to show in Phase 2 study ( randomized double blind placebo controlled) significant results AT DAY 3- 90% of patients showed significant improvement in symptoms vs. Placebo arm at 70%. ****Or what ever is the most compelling. We could add links like the MOA and study.
What do you think? Board?
Headline " CytoDyn a small biotech, submits to FDA its' COVID 19 drug, Leronlimab, for EUA approval. Leronlimab, an Immune Modulator, is the FIRST DRUG in the MM category to show in Phase 2 study ( randomized double blind placebo controlled) significant results AT DAY 3- 90% of patients showed significant improvement in symptoms vs. Placebo arm at 70%. ****Or what ever is the most compelling. We could add links like the MOA and study.
What do you think? Board?
(4)
(1)
